The Chief Financial Officer of Ligand Pharmaceuticals has sold $688,000 worth of company stock, following an 80% surge in the company's shares over the past year.

Ligand Pharmaceuticals has released key highlights from its fourth-quarter earnings call, detailing its financial performance and outlook.

Ligand Pharmaceuticals has received a new 'Buy' rating from Bank of America, citing the company's high-margin exposure to biopharma growth and a less risky business narrative.

Ligand Pharmaceuticals is preparing to announce its fourth-quarter 2025 earnings, with a preview detailing expectations for the company.

Ligand Pharmaceuticals has filed for a mixed shelf offering, indicating plans to raise capital through various securities.